- Home
- UNB vs UNCY Comparison
UNB vs UNCY Comparison
Compare UNB & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UNB | UNCY |
|---|---|---|
| Founded | 1891 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 121.9M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UNB | UNCY |
|---|---|---|
| Price | $23.75 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 11.2K | ★ 394.5K |
| Earning Date | 01-14-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.07% | N/A |
| EPS Growth | ★ 27.30 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $52,533,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | ★ 13.25 | N/A |
| 52 Week Low | $20.65 | $3.71 |
| 52 Week High | $36.00 | $11.00 |
Technical Indicators
Market Signals| Indicator | UNB | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 52.72 |
| Support Level | $22.96 | $6.31 |
| Resistance Level | $23.95 | $6.95 |
| Average True Range (ATR) | 0.68 | 0.42 |
| MACD | 0.17 | -0.04 |
| Stochastic Oscillator | 66.82 | 35.71 |
Price Performance
Historical ComparisonAbout UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.